|AHFS/Drugs.com||International Drug Names|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||327.424 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Benactyzine is an anticholinergic drug that was used as an antidepressant in the treatment of depression and associated anxiety before it was pulled from the U.S. market by the FDA due to its ineffectiveness.
Its use for these indications was limited by side effects such as dry mouth and nausea, and at high doses it can cause more severe symptoms such as deliriant and hallucinogenic effects. "Large doses of benactyzine in normal subjects may produce a state resembling the action of mescaline or LSD."
Brand names have included: Suavitil, Phebex, Phobex, Cedad, Cevanol, Deprol, Lucidil, Morcain, Nutinal, Parasan. While there was some tentative evidence of effectiveness when combined with meprobamate, with the medication no longer available it is not clinically important.
- Shorter E (December 2002). "Looking backwards: a possible new path for drug discovery in psychopharmacology". Nature Reviews. Drug Discovery. 1 (12): 1003–6. doi:10.1038/nrd964. PMID 12461521. S2CID 23439533.
- Fisher S (1959). Child Research In Psychopharmacology (1st ed.). Springfield, Illinois: Charles C Thomas Pub. p. 13.
- DeBattista AF, Schatzberg JO, Cole C (2010). Manual of clinical psychopharmacology (7th ed.). Washington, DC: American Psychiatric Pub. p. 423. ISBN 978-1-58562-377-8.
- Smith MC (2013). "Market Behavior". Principles of Pharmaceutical Marketing (Third ed.). New York: Routledge. ISBN 978-1-317-94071-5.
- Media related to Benactyzine at Wikimedia Commons